In human skin, two main populations of dendritic cells (DC) 
Introduction
Dendritic cells (DC) are professional antigen presenting cells (APC) with the unique ability to initiate and maintain primary immune responses. As key sensors of danger, immature DC reside in peripheral tissues, such as the skin and mucosal sites. DC are specialized in antigen capture and constantly sample the environment for antigens, local inflammation and pathogens (1) (2) (3) (4) . Upon recognition of danger signals, immature DC undergo a process called DC maturation, resulting in the inhibition of antigen uptake, as well as in a switch in chemokine receptor expression and subsequent migration of the DC to the secondary lymphoid organs, where they present the antigen to T cells. In the human skin, two main populations of DC can be discriminated, Langerhans cells (LC), which can be found in the epidermis (5, 6) and dermal DC (DDC), which are located in the dermis. In vitro differentiation studies from CD34 + precursor cells suggest that DDC and LC originate from a common myeloid DC precursor and have several features in common. These include the expression of high levels of MHC class I and class II molecules, co-stimulatory and adhesion molecules, as well as the expression of certain leukocyte/myeloid markers such as CD45RO, CD13 and CD33 and a lack of CD3, CD19, CD20, CD16 and CD56 lineage markers as reviewed by Larregina and co-workers (7).
However, both DC subsets also exhibit specific "DDC" and "LC" characteristics. LC are characterized by the expression of the C-type lectin Langerin, which is responsible for the formation of Birbeck granules, a typical hallmark for the LC lineage (8, 9) . In addition, LC express E-cadherin (10), membrane adenosine triphosphatase (ATPase) and CCR6 (11) , whereas DDC do not. On the other hand, DDC can be distinguished from LC by the expression of certain C-type lectins, such as macrophage mannose receptor (MMR) and DC-SIGN (12, 13) , as well as by the expression the scavenger receptor CD36 (14) and the expression of coagulation factor XIIIa (FXIIIa) (15, 16) .
Furthermore, DDC can also express the monocyte/macrophage marker CD14 (5, 6, 17) .
Although it has been described that both DDC and LC are professional APC capable of inducing primary immune responses in vitro and in vivo, functional differences between the DC subsets have also been reported. The observed difference in C-type lectin expression indicates that both DC subsets may recognize and react to different spectra of pathogens (18) . Besides that, in vitro generated DDC have been described to more efficiently drive the differentiation of naïve B cells into IgM-secreting plasma cells, while LC have been described to be more potent in vitro stimulators of cytotoxic T cells (19) , as well as more potent inducers of Th1 responses due to their inability to produce IL-10 upon CD40 ligation (6) . However, compared to the abundant in vitro data, data clarifying in vivo functions of human LC are scarce. Recently, immunogenic properties of LC in vivo have been questioned based on murine studies. Rather than directly activating immune effector cells, LC were reported to function as transporters of antigen, carrying antigen from skin to lymph nodes (LN) and transferring the antigenic cargo to LN-resident DC for actual antigen presentation and CTL priming (20) (21) (22) .
It must be emphasized that most of our current knowledge on DDC and LC phenotype and function was obtained through the study of DDC and LC cultured in vitro from CD34+ HPC or bloodderived monocytes (5, 19, 23, 24) . Analyzing DC migrated from skin explants or directly isolated from epidermal and dermal cell suspensions revealed that the skin DC population is quite heterogeneous. 
Materials and Methods

Isolation of Dermal Dendritic Cells and Langerhans Cells from Skin.
Human skin specimens were obtained from healthy donors undergoing corrective breast or abdominal plastic surgery after informed consent. 3-mm thick slices of skin containing both the epidermis and the dermis were cut by use of a dermatome. Slices of skin were cut in pieces of 1 cm2
and incubated with 2.4 U/ml Dispase II (Roche Diagnostics, Mannheim, Germany) for 30 -60 minutes at 37ºC. The epidermis and dermis were separated with tweezers and washed with PBS. To isolate LC, the epidermal sheets were incubated with PBS with 0,05 % trypsin (Invitrogen Life Technologies, Carlsbad, CA) for 10 minutes at 37ºC, and single-cell suspension was prepared by pushing the tissue through 100-µm pore nylon cell strainers (Falcon) with a plunger of a 2-ml syringe. Epidermal cell suspension were enriched for LC by density centrifugation over Lymphoprep (Nycomed AS, Oslo, Norway) and CD1a-guided magnetic cell sorting (MACS; Miltenyi Biotec, Bergisch Gladbach, Germany). To isolate dermal DC, the dermis was incubated with PBS containing 0.48 U/ml Dispase and 6 mg/ml Collagenase A (Boehringer Mannheim, Mannheim, Germany) at 37ºC for 2 hours, after which single cell suspension was prepared by pushing through 100-µm pore nylon cell strainers with a plunger of a 2-ml syringe. Cell suspension was enriched for DDC by CD1a-guided magnetic cell sorting (MACS).
Antibodies and Flow Cytometry. 
PE-or FITC-labeled
Preparation of cRNA and gene chip hybridization.
RNA isolation and gene chip hybridization was performed as described (31) . Briefly, cell pellets of skin isolated DDC and LC, from 3 different donors, were dissolved in TRIzol Reagent (Life Technologies) and stored at -20ºC. After chloroform extraction, total RNA was precipitated in isopropanol, rinsed with 70% ethanol, lyophilized, and dissolved in 10 μl of distilled water.
Fragmentation, hybridization, and scanning of the Human Genome U133 Plus 2.0 Arrays were performed according to the manufacturer's protocol (Affymetrix, Santa Clara, CA). The preparation of labeled cRNA was performed according to the Two-cycle Eukaryotic Target Labeling assay protocol, using the GeneChip Expression 3' amplification two-cycle labeling and control reagents kit (Affymetrix).
Briefly, cDNA was generated from total RNA (20-150 ng), using SuperScript II (Invitrogen Life Technologies) and a T7-oligo(dT) promoter primer (Affymetrix). After a second-strand cDNA synthesis, cDNA was converted to cRNA by an in vitro transcription reaction (Ambion MEGAscript T7 kit. Foster City, CA). Thereafter, the cRNA was purified using RNeasy Mini kit (Qiagen, Hilden, Germany), and the yield was controlled with a spectrophotometer. A second cycle of cDNA synthesis was performed, followed by the same cleanup as above and a second in vitro transcription reaction cycle with biotinlabeled ribonucleotides and T7 RNA polymerase. Labeled cRNA was purified, using RNeasy Mini kit (Qiagen), quality controlled with Agilent 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA), and denatured at 94°C before hybridization. The samples were hybridized to the Human Genome U133 Plus 2.0 Array at 45°C for 16 h by rotation (60 rpm) in an oven. The arrays were then washed, stained with streptavidin-PE (Invitrogen Molecular Probes), washed again, and scanned with a GeneArray Scanner (Affymetrix).
Microarray data analysis.
The fluorescence intensity was analyzed, using the GeneChip Operating Software (GCOS) 1.1 (Affymetrix), and scaled to a target value of 100. Further data analysis was performed with GeneSpring 
Results and Discussion
Phenotyping CD1a + DDC and LC by flow cytometry.
Dermal and epidermal cell suspensions were analyzed for the presence of DC by flow cytometry.
As shown in figure 1A , CD1a + DC could be detected in both dermal (top left panel) and epidermal cell suspensions (bottom left panel). Next, DC were isolated from the dermal and epidermal suspensions on the basis of the pan-skin DC marker CD1a. Purity of CD1a + dermis-derived DC (hereafter referred to as CD1a + DDC) and CD1a + epidermis-derived LC (hereafter referred to as LC) were more than 90%. As shown in Figure 1A , CD1a + DDC exhibit DDC characteristics, expressing intermediate levels of CD1a and no Langerin (top right panel), whereas skin LC exhibit LC characteristics, expressing high levels of CD1a and Langerin (lower right panel). The isolated LC displayed an immature phenotype, as indicated by the absence of CD83 expression, whereas the CD1a + DDC expressed CD83, indicative of mature phenotype ( Figure 1A and B) . Importantly, this differential expression of CD83 was also observed for CD1a + cells in freshly prepared dermal and epidermal cell suspensions (see Figure 1A) , suggesting that CD83 expression was not induced by the isolation procedure. In addition, both DC subsets exhibit similar levels of the co-stimulatory and adhesion molecules CD86
and HLA-DR ( Figure 1C ). 
Phenotyping CD1a
+ DDC and LC by transcriptional analysis.
To make an extensive transcriptional comparison of CD1a + DDC and LC, RNA isolated from each DC subset was hybridized to Affymetrix Human Genome U133 Plus 2.0 arrays containing >54,000
probe sets and covering 38,500 human genes. mRNA expression profiles of CD1a + DDC and LC were assessed from 3 individual donors. To determine whether the isolated CD1a + DDC and LC indeed represented true DDC and LC, both DC subsets were first subjected to a global transcriptional analysis and markers associated with DDC and LC biology were extracted. For each subset, the intensity signals for selected marker genes that were expressed (denoted present) and had an intensity level of >200 were assessed. As shown in Table I , the transcriptional patterns of CD1a + DDC and LC fully support previous reports on DDC and LC phenotype definitions (32, 33) . CD1a + DDC express the C-type lectins MMR and DC-SIGN, the scavenger receptor CD36, coagulation FXIIIa and the chemokine receptor CCR5, but do not express markers associated with LC phenotype such as Langerin, membrane ATPase (CD39) and CCR6, while skin LC express the C-type lectin Langerin, membrane ATPase and the chemokine receptor CCR6 (Table I) , but do not express MMR, DC-SIGN, CD36 or FXIIIa (Table I) . Based on this panel of DC subset-defining markers (Table I) , we thus conclude that CD1a + DDC adhere to the previously proposed definition of the DDC phenotype and are not likely to represent migratory LC, as also described by others (26) . In particular the observation that CD1a+ DDC express DDC-defining markers associated with an immature phenotype such as DC-SIGN and MMR, argues against the possibility of migrating LC adopting a skin DDC transcriptional profile under the influence of environmental (i.e. dermal) factors, as "de novo" expression of such a marker is not consistent with the degree of maturation that might be expected in migrating LC. LC display a non-immunogenic, non-migratory phenotype under steady-state conditions.
In order to gain insight into functional differences between CD1a + DDC and LC, genes that were differentially expressed (2-fold change in expression level, p<0.05) were further clustered into groups, as illustrated by a heat map in Figure 2 . Seven groups of differentially expressed genes are presented according to function: chemokines/chemokine receptors, interleukins/interleukin receptors, TNF/TNF receptor family, adhesion, immune responses, endo/exocytosis and "others". In addition, to further characterize both DC subsets, a panel of genes was selected based on their specific known function in DC biology (Table II A (Table II. B), as also described by others (10, (34) (35) (36) (37) . Indeed, ligation of CD47, also known as Furthermore, these data support previously described findings that LC trafficking is not only controlled at the level of chemokine/chemokine receptor expression, but also at the level of cell adhesion (32, 40) . In addition, LC express relatively low levels of co-stimulatory and adhesion molecules such as CD80, CD40 and CD54 (Table II. A), or pro-inflammatory cytokines and cytokine receptors (Table II.C) , and do not express T cell stimulation molecules such as 4-1BB and CD30L, indicating that under steady state conditions LC are poor T cell stimulators (Table II .E). The LC's non-T cell stimulatory profile is further illustrated by the expression of CD43 (also known as leukosialin), a glycoprotein that is only expressed on immature dendritic cells and implicated in the inhibition of nonspecific T cell contacts (41, 42) . In addition, under steady state conditions LC also do not exhibit proper B cell stimulatory capacity, as illustrated by the absence of B cell activating factor (BAFF), a TNF family member, which is known to play an important role as a co-stimulator of B lymphocyte proliferation and function (43) . 
CD1a
+ DDC display an activated and migratory phenotype under steady-state conditions.
In stark contrast to LC, CD1a + DDC exhibit an activated phenotype, expressing higher levels of co-stimulatory and adhesion molecules (e.g. CD54, CD80, CD86, CD40; see and SDF-α (CXCL12). In addition, CD1a + DDC also expressed chemokine receptors that are involved in lymph node homing such as CCR7 and CXCR4 (Table II.B) .
The more activated immuno-stimulatory phenotype of CD1a + DDC as compared to LC, was also confirmed by the expression CD44, C3aR1 and C5aR1. CD44 has been described to be up-regulated on skin DDC and LC upon activation, and to be involved in emigration from the skin and in adhesion to the T cell zones of the lymph nodes, thereby showing its importance for the ability of DC to induce primary T cell responses within the LN (44) . As shown in Figure 2 , CD44 is significantly up-regulated on CD1a + DDC compared to skin LC, indicating that indeed CD1a + DDC exhibit a more activated phenotype capable of T cell binding in the LN. This more activated phenotype was further illustrated by the observation that CD1a + DDC, but not LC, expressed the complement receptors C3aR1 and C5aR1, both of which are involved in DC homing to inflammatory sites. This is in line with findings from others, demonstrating that freshly isolated CD83 + skin DC expressed both C3aR1 and C5aR1 (45), whereas C5aR1 was not observed in the majority of immature skin LC (46) . Moreover, the previously reported observation that C5aR1 was expressed on a small number of skin LC that were located in the proximity of the basal membrane and exhibited a more activated and migratory phenotype, further supports the apparent association between complement receptor expression and maturation induction (46) . transcripts. The anti-inflammatory cytokine IL-10 has been described to negatively regulate the immune response either via the induction of T cell tolerance (47) or the development of regulatory T cells (48, 49) and IDO has been described to convey immunosuppressive effects by degrading the essential amino acid tryptophan, thereby down-regulating T cell functions (50, 51 
Mature
